Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper

Annals of Oncology

Volumn 26, Issue 2, 2015, Pages 300-306

  Casali, Paolo G ^a   Bruzzi, P ^b   Bogaerts, J ^c   Blay, J Y ^d   Aapro, M ^e   Adamous, A ^f   Berruti, A ^g   Bressington, J ^h   Bruzzi, B ^b   Capocaccia, R ⁱ   Cardoso, F ^j   Celis, J E ^k   Cervantes, A ^l   Ciardiello, F ^m   Claussen, C ⁿ   Coleman, M ^o   Comis, S ^p   Craine, S ^q   De Boltz, D ^r   De Lorenzo, F ^s   Dei Tos, A P ^t   Gatta, G ^a   Geissler, J ^u   Giuliani, R ^v   Grande, E ^w   Gronchi, A ^a   Jezdic, S ^x   Jonsson, B ^y   Jost, L ^z   Keulen, H ^aa   Lacombe, D ^ab   Lamory, G ^ac   Le Cam, Y ^ad   Leto di Priolo, S ^p   Licitra, L ^a   Macchia, F ^ad   Margulies, A ^ae   Marreaud, S ^ab   McVie, G ^af   Narbutas, S ^s   Oliver, K ^ag   Pavlidis, N ^ah   Pelouchova, J ^s   Pentheroudakis, G ^ai   Piccart, M ^aj   Pierotti, M A ^a   Pravettoni, G ^ak   Redmond, K ^ah   Riegman, P ^al   Ruffilli, M P ⁿ   Ryner, D ^q   Sandrucci, S ^am   Seymour, M ^an   Torri, V ^ao   Trama, A ^a   Van Belle, S ^ap   Vassal, G ^aq   Wartenberg, M ^ar   Watts, C ^ae   Wilson, A ^r   Yared, W ^as   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c EORTC DATA CENTER   (Belgium)

^d CENTRE LÉON BÉRARD   (France)

^e CLINIQUE DE GENOLIER   (Switzerland)

^f House of Representatives   (Cyprus)

^g SPEDALI CIVILI   (Italy)

^h GIST Support UK PAWS GIST   (United Kingdom)

ⁱ ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^j Champalimaud Cancer Center   (Portugal)

^k ECCO   (Belgium)

^l UNIVERSITY OF VALENCIA   (Spain)

^m SECOND UNIVERSITY OF NAPLES   (Italy)

ⁿ PFIZER INC   (United States)

^o LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^p NOVARTIS   (Switzerland)

^q CML Support Group UK   (United Kingdom)

^r Rarer Cancers Foundation UK   (United Kingdom)

^s European Cancer Patient Coalition   (Belgium)

^t European Society of Pathology   (Belgium)

^u CML Advocates Network   (Switzerland)

^v SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^w GETHI   (Spain)

^x ESMO   (Switzerland)

^y MEDICAL PRODUCTS AGENCY   (Sweden)

^z UNIVERSITY HOSPITAL BASEL   (Switzerland)

^aa Chordoma Foundation   (United States)

^ab EORTC   (Belgium)

^ac SANOFI   (France)

^ad EURORDIS   (France)

^ae European Oncology Nursing Society   (United Kingdom)

^af eCancer   (Switzerland)

^ag International Brain Tumor Alliance   (United Kingdom)

^ah ESO   (Greece)

^ai UNIVERSITY OF IOANNINA   (Greece)

^aj ECCO   (Denmark)

^ak UNIVERSITY OF MILAN   (Italy)

^al ERASMUS MEDICAL CENTER   (Netherlands)

^am Esso   (Canada)

^an National Cancer Research Network (NCRN)   (United Kingdom)

^ao MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^ap GHENT UNIVERSITY HOSPITAL   (Belgium)

^aq The European Society for Pediatric Oncology   (Belgium)

^ar Sarcoma Patients EuroNet   (Germany)

^as Association of European Cancer Leagues   (Belgium)

more..

Author keywords

Clinical trials; Rare cancers; Research methodology

Indexed keywords

TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; CANCER SURVIVAL; CASE FINDING; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CONCEPTUAL FRAMEWORK; DATA BASE; ELECTRONIC MEDICAL RECORD; EUROPE; HEALTH CARE QUALITY; HUMAN; NEOPLASM; PATIENT INFORMATION; PRIORITY JOURNAL; RARE CANCER; RARE DISEASE; REIMBURSEMENT; REVIEW; STUDY DESIGN; TREATMENT RESPONSE; METHODOLOGY; PRACTICE GUIDELINE; PROCEDURES;

CLINICAL STUDIES AS TOPIC; HUMANS; NEOPLASMS; RARE DISEASES; RESEARCH DESIGN;

EID: 84925297669     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu459     Document Type: Review

References (27)

1. Gatta G, van der Zwan JM, Casali PG et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011; 47: 2493-2511.
2. Thornton JG, Lilford RJ, Johnson N. Decision analysis in medicine. Br Med J 1992; 304: 1099-1103.
3. Eichler HG, Bloechl-Daum B, Brasseur D et al. The risks of risk aversion in drug regulation. Nat Rev Drug Discov 2013; 12: 907-916.
4. Behera M, Kumar A, Soares HP et al. Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control 2007; 14: 160-166.
5. Tan SB, Dear KB, Bruzzi P, Machin D. Strategy for randomised clinical trials in rare cancers. Br Med J 2003; 327: 47-49.
6. Piantadosi S. Principles of clinical trial design. Semin Oncol 1988; 15: 423-433.
7. Gerss JW, Ko¨pcke W. Clinical trials and rare diseases. Adv Exp Med Biol 2010; 686: 173-190.
8. Ellis LM, Bernstein DS, Voest EE et al. American Society of Clinical Oncology Perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014; 32: 1277-1280.
9. Lee JJ. Demystify statistical significance-time to move on from the p value to Bayesian analysis. J Natl Cancer Inst 2011; 103: 2-3.
10. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2011; 9: 199-207.
11. Mauer M, Collette L, Bogaerts J; European Organisation for Research and Treatment of Cancer Statistics Department. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size. Eur J Cancer 2012; 48: 1386-1391.
12. Adamina M, Tomlinson G, Guller U. Bayesian statistics in oncology: a guide for the clinical investigator. Cancer 2009; 115: 5371-5381.
13. Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. Br Med J 1995; 311: 1621-1625.
14. Buyse M, Sargent DJ, Grothey A et al. Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 2010; 7: 309-317.
15. Karnofsky DA. Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin Pharmac Ther 1961; 2: 709-712.
16. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
17. Eisenhauer EA. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. Ann Oncol 1998; 9: 1047-1052.
18. Moliner AM. Creating a European Union framework for actions in the field of rare diseases. Adv Exp Med Biol 2010; 686: 457-473.
19. Tucker ME. How should clinical trial data be shared? Br Med J 2013; 347: f4465.
20. Middleton LP, Feeley TW, Albright HW et al. Second-opinion pathologic review is a patient safety mechanism that helps reduce error and decrease waste. J Oncol Pract 2014; 10: 275-280.
21. Santiago TC, Jenkins JJ. Histopathologic diagnosis of pediatric neoplasms: a review of international consultations. Arch Pathol Lab Med 2013; 137: 1648-1653.
22. Ray-Coquard I, Montesco MC, Coindre JM et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Ann Oncol 2012; 23: 2442-2449.
23. Eichler HG, Oye K, Baird LG et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012; 91: 426-437.
24. Casali PG. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 2007; 18: 1923-1925.
25. Sheehan M, Martin J. Can broad consent be informed consent? Publ Health Ethics 2011; 4: 226-235.
26. Steinsbekk KS, Myskja BK, Solberg B. Broad consent versus dynamic consent in biobank research: is passive participation an ethical problem? Eur J Hum Gen 2013; 21: 897-902.
27. Andersen MR, Storm HH; on behalf of the Eurocourse Work Package 2 Group. Cancer registration, public health and the reform of the European data protection framework: abandoning or improving European public health research? Eur J Cancer 2013 October 10 [Epub ahead of print], doi: 10.1016/j.ejca.2013.09.005.